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ABSTRACT 
The utility and effectiveness of whole exome sequencing (WES) have been demonstrated in a 
pediatric setting, and for this reason, it has recently begun being offered in in the prenatal setting.  
The scope of exome sequencing and the possibility for incidental findings raises ethical concerns 
and challenges current resources available to prenatal genetic counselors to implement this 
testing. This creates a need to understand genetic counselors’ opinions toward such a test prior to 
its implementation. For this reason, a survey focusing on clinical scenarios and factors 
influencing genetic counselors’ opinions on prenatal WES was distributed to clinical prenatal 
counselors and laboratory counselors through the National Society of Genetic Counselors’ 
student research survey program. One hundred and sixty respondents met criteria for and 
completed the survey. Results of this survey were analyzed for descriptive statistics as well as 
comparison of responses using nonparametric analysis. Responses showed that 59.4% of 
respondents were comfortable with prenatal WES as a diagnostic tool after other diagnostic 
testing had come back negative or inconclusive. Support for use of prenatal exome sequencing 
increased significantly (p=0.0088) in the context of targeted prenatal exome (TES), with 74.4% 
of counselors supporting TES after other diagnostic testing was negative or inconclusive. The 
two largest factors influencing opinions and support of prenatal exome sequencing were the 
perceived ability of patients to handle the amount of information provided by the testing (n=125) 
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and the clinical utility of exome sequencing in the prenatal setting (n=123). Most genetic 
counselors (70.7%) were more likely to support prenatal exome sequencing if educational 
resources were provided to aid in the implementation of the testing. Overall, 46.9% of genetic 
counselors would support this testing if it were restricted to cases with clear clinical indications, 
while an additional 31.9% would support prenatal TES only. The public health significance of 
this study is that, because prenatal WES/TES will likely be clinically available in the near future, 
understanding genetic counselors’ perceptions of testing and barriers to uptake will help to more 
seamlessly integrate this testing into the clinic to provide the most benefit and least harm to 
prenatal patients. 
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1.0  INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Exome Sequencing 
Exome sequencing is a type of germline genetic testing that can analyze the entire protein-coding 
region of a genome (exons). This region accounts for approximately 1% of the human genome, 
while encompassing approximately 85% of disease-causing mutations.1,2 Exome sequencing may 
be ordered through many commercial and academic laboratories, either as whole exome 
sequencing (WES), which analyzes the entire exome, or as targeted exome sequencing (TES), 
which analyzes only those exons and genes therein with mutations known to be associated with a 
particular phenotypic expression. The definition of TES may vary from laboratory to laboratory, 
but generally involves sequencing the entire exome and only reporting out variants related to 
either the patient’s phenotype, or a set of disorders with similar phenotypes (e.g. myopathy, 
skeletal dysplasia).3 
Currently, this technology is largely used in the setting of patients for whom all other 
genetic testing options have been exhausted and is not clinically offered to healthy individuals. 
Patients who undergo exome sequencing have often endured a drawn-out “diagnostic odyssey” 
that can be both fiscally and emotionally costly. Most frequently, these patients are children.4 
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Common clinical features in these patients include intellectual disability, developmental delay, 
epilepsy/seizures, brain MRI abnormalities, and/or multiple congenital anomalies.5,6 In this 
setting, exome sequencing can help to identify rare disorders and provide patients and their 
families with an answer for their symptoms. WES identifies a clinically actionable finding in 
approximately 30% of cases.5,6 This diagnostic yield increases slightly in the context of “trio” 
sequencing, in which two additional blood relatives (typically the proband’s parents) are 
sequenced with the proband. In cases where the entire trio is sequenced, the detection rate can 
range from 31-37% compared to approximately 23% when only the proband is sequenced.5,6 Trio 
sequencing can help to determine segregation patterns of variants of interest, in addition to 
supporting evidence for or against a particular variant’s pathogenicity. Trio sequencing can also 
aid in variant interpretation and raw data analysis, particularly in areas with otherwise low 
sequencing coverage.7 
1.1.2 Incidental Findings 
Because WES analyzes the entire exome, this introduces the possibility for incidental findings 
unrelated to patient phenotype arises. The American College of Medical Genetics (ACMG) 
defines an incidental finding as “any clinically actionable result that is not associated with the 
phenotype for which initial testing was conducted.”8 Some ethical controversy has arisen around 
the return of incidental findings, particularly for adult-onset conditions in pediatric patients. For 
this reason, the ACMG released recommendations for the return of incidental findings in whole 
genome and exome sequencing; this includes a list of 57 genes for which it is recommended that 
pathogenic or likely pathogenic findings always be returned (this list has since been altered to 
exclude one gene, making it 56 reportable genes, however at the time of the initial 
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recommendation, 57 genes were listed). Mutations in these genes cause conditions for which 
there exists some form of treatment, surveillance, or intervention to help prevent or alleviate 
symptoms.8 The recommendations laid out by the ACMG indicate that incidental findings should 
be returned to the clinician by the laboratory performing testing regardless of the age of the 
patient. The laboratory has a responsibility to report the recommended 57 genes; any genes 
outside of this minimum list may be reported at the laboratory’s discretion. 8 Adequate pre- and 
post-test counseling should be provided by the clinician to help guide patient understanding of 
the possibility of incidental findings. Adequate counseling includes informing the patient that 
they may opt out of incidental finding analysis, as well as the benefits and risks of doing so.8,9 
Targeted exome sequencing eliminates the return of incidental findings by narrowing the 
sequencing search to genes known to be associated with a particular clinical phenotype.  
The National Society of Genetic Counselors (NSGC) has also issued a position statement 
on incidental findings.10 This statement advises that a plan for the return of incidental findings 
results be made during the pre-test counseling appointment, establishing which categories of 
results will or will not be returned. In addition, it specifies that healthcare providers outside of 
genetics who are ordering WES for their patients should ensure that the patient has access to a 
genetics professional, such as a genetic counselor, throughout the testing and results disclosure 
process.10 
1.1.3 Informed Consent 
The scope of exome sequencing creates a need for a unique counseling process both before and 
after testing. The ACMG recommends that this counseling be performed by a trained genetic 
counselor or geneticist and that this counseling process include the following information: 
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express written documentation of consent either from the patient or the patient’s legal guardian; 
the availability of interventions or treatments for incidental findings; the possible and expected 
outcomes of testing; which incidental findings should be included as well as the likelihood of 
identifying incidental findings; the risks, benefits, and limitations of testing as well as 
implications results will have for family members; a clear delineation between research and 
clinical testing; and the option to opt in or out of research.11 These recommendations also state 
that WES should only be offered to minors in the context of phenotypically-driven diagnostic 
testing, when results would allow for early monitoring or intervention, and/or in IRB-approved 
research studies.11 
There have been studies conducted that further emphasize the importance of informed 
consent in relation to WES/genomic information. Testing of pre- and post-consent knowledge of 
genome sequencing showed a significant increase (p<0.0001) in understanding of the benefits 
and limitations of the testing, regardless of sociodemographic characteristics, when informed 
consent is obtained. General public knowledge about exome sequencing may be limited, 
highlighting the importance of the informed consent process in educating patients to make the 
most informed decisions about their own testing choices.12 
1.1.4 Prenatal Testing 
Many testing options are currently available to patients in the prenatal setting. The majority of 
these tests are screening tests, providing an adjusted risk for two or three of the most common 
live-born trisomies (13, 18, 21; some tests do not screen for 13), or for neural tube defects. 
Screening tests available prenatally include first-trimester maternal serum screening, second-
trimester maternal serum screening (quad screen), and cell-free fetal DNA (also referred to as 
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non-invasive prenatal testing/screening, NIPT, or NIPS).13 Screening comes with a higher 
potential for false positives, and in the context of genetic counseling, it is usually recommended 
that the results of these tests be confirmed with diagnostic testing.  
It is important to also note that ultrasound imaging is itself a screening procedure. 
Detailed anatomy ultrasounds performed at 18-20 weeks gestation can provide information about 
structural fetal anomalies, including cardiac anomalies and brain abnormalities. Ultrasound is 
able to detect approximately 50% of all cases of Down Syndrome (trisomy 21) and 80-90% of all 
cases of trisomy 13 and 18.14 The efficiency of ultrasound screening is dependent upon the 
technician and/or doctors performing and interpreting the images as well as the age of gestation. 
Structural anomalies may be more or less difficult to observe earlier or later than 18-20 weeks 
gestation.14 Ultrasound is the standard method for obtaining a fetal phenotype, and thus has 
limitations not seen in pediatric and adult settings, where a much more detailed phenotype can be 
observed. 
Prenatal diagnostic testing typically entails either chorionic villus sampling (CVS) or 
amniocentesis depending on the gestational age. These tests come with a 1/250 to 1/1000 risk of 
miscarriage or early labor depending on the facility in which they are being performed and the 
skill level of the physician performing the procedure.15 Frequently, diagnosis consists of 
confirmation of aneuploidy through fluorescence in situ hybridization (FISH) and/or 
karyotyping.16 Karyotyping may also detect other structural chromosomal abnormalities such as 
unbalanced translocations, inversions, and large-scale deletions and duplications (>3MB).16 
Fluorescence in situ hybridization can detect known microdeletions or microduplications no 
smaller than 190 kb.16,17 However, sometimes more detailed analysis is warranted. Parents may 
be known carriers of an autosomal recessive condition or a single parent may have a known 
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autosomal dominant condition, including monogenic disorders and 
microdeletion/microduplication syndromes for which the pathogenic mutation is too small for 
detection via FISH or karyotyping. These conditions may be screened for via single mutation, 
single gene, or chromosomal microarray analysis (CMA) using CVS or amniocentesis samples. 
1.1.5 Chromosomal Microarray Analysis 
Chromosomal microarray analysis (CMA) is a type of genetic testing that analyzes chromosomes 
for deletions and duplications via array comparative genomic hybridization (aCGH) and/or 
single-nucleotide polymorphism(SNP)-array.18 Array CGH allows for comparisons of the 
amount of chromosome material on each chromosome between a patient sample and a control 
sample. This helps to determine if the patient being tested has any extra or missing pieces of their 
chromosomes. Using this testing, unique microdeletions and microduplications can be detected 
that are sometimes associated with a syndromic presentation.19 The drawback of using aCGH is 
that it cannot detect copy neutral chromosomal aberrations or triploidy. SNP-based arrays allow 
for detection of copy-neutral changes such as loss of heterozygosity associated with 
consanguinity or uniparental disomy (UPD), but have limited ability to detect copy number-
variants.18 For this reason, many clinicians now utilize both forms of microarray at once through 
a combination platform, allowing for greater detection rates.18 
Prenatally, CMA is used to detect aneuploidy or UPD, to identify possible CNVs in cases 
where structural fetal abnormalities have been identified on ultrasound, and to detect known 
familial microdeletions or microduplications too small for FISH analysis.19 In cases of structural 
fetal anomalies, CMA identifies causative deletions or duplications in approximately 6% of cases 
with normal karyotypes.19 In cases where the only indication is advanced maternal age, CMA 
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detects causative deletions or duplications in 1.7% of cases with a normal karyotype.19 CMA is 
now frequently being used in lieu of karyotyping for prenatal diagnosis due to this higher 
detection rate, excluding detection for copy neutral aberrations such as translocations and 
inversions.19  
Due in part to concerns for the appropriate use of CMA prenatally, the American 
Congress of Obstetricians and Gynecologists (ACOG) released a policy statement in 2013 with 
recommendations regarding this testing in the prenatal setting.20 These recommendations suggest 
that in fetuses with one or more structural fetal abnormalities, CMA can replace the need for 
karyotyping, but that either CMA or karyotyping can be performed in fetuses with no identified 
structural abnormalities. In addition, it is recommended that this test not be restricted solely to 
women of advanced maternal age, as most CMA findings are not associated with maternal age. 
CMA is recommended in cases of fetal demise or stillbirth due to the increased likelihood of 
obtaining results. Most importantly, ACOG recommends comprehensive pre- and post-test 
counseling and documented informed consent for all prenatal CMA.20 
Microarray is perhaps the most analogous testing to exome sequencing that is currently 
available in the prenatal setting.  The broad scope of coverage provided by CMA leads to a 
higher likelihood for VUS results and incidental findings unrelated to the patient’s phenotype.21 
The possibility for more uncertainty or unexpected results leads to a lengthier and more 
information-heavy pre- and post-test counseling/informed consent process.20 For this reason, it is 
important to consider the ethical arguments and clinician responses that followed the 
introduction of CMA into the prenatal setting, as these may predict how healthcare providers 
handle the possible introduction of exome into the prenatal setting. 
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1.1.6 Variants of Uncertain Significance 
A side-effect of the broad scope of exome sequencing and CMA is the increased likelihood of 
returning variants of uncertain significance (VUS). These are variants for which not enough data 
is available to classify the finding as either pathogenic or benign. Variants of uncertain 
significance can present a challenge in post-test counseling, as it may be difficult to properly 
explain the meaning of this result. In addition, many patients may leave the session believing that 
the VUS is a diagnosis, regardless of the skill of the counselor providing post-test counseling.22 
In the context of TES, VUS results will most likely be identified because the gene in which the 
VUS was found is associated with at least one of the patient’s symptoms. Patients or their 
families may latch onto these similarities, despite not having other major symptoms associated 
with mutations in that particular gene.22 This emphasizes the importance of comprehensive pre- 
and post-test counseling to best educate patients on the ambiguous nature of VUS results.11  
Variants of uncertain clinical significance are detected in anywhere from 1.5-3.5% of 
prenatal CMA cases. VUS in the prenatal setting creates unique ethical concerns and counseling 
complications, as many prenatal patients are anxious about any perceived “abnormal” result from 
prenatal testing and may alter pregnancy management decisions based on such results. Unlike in 
the pediatric or adult setting, where phenotype helps to guide VUS interpretation, limited 
phenotypic information is available in the prenatal setting, making VUS interpretation more 
difficult. In addition to the concern of VUS results from CMA, parents may wish to test their 
current pregnancy for a VUS result detected in the context of pediatric or fetal demise testing in 
a previous child, particularly if the VUS is in a plausible candidate gene matching many of the 
previous child’s symptoms.23  
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1.1.7 Clinician Response to Prenatal Chromosomal Microarray 
While CMA is now relatively commonplace in the prenatal setting, its introduction caused some 
challenges to the genetic counseling process. A major concern expressed by prenatal counselors 
regarding CMA was the uncertainty of VUS results, and the inability to quantify that risk for 
patients.24 According to many counselors, this in turn weakened their confidence in providing 
patients with guidance on pregnancy management decisions.24 In addition to the concern with 
VUS results, counselors stated that counseling was further complicated by a general lack of data 
in the literature on many of the deletions and duplications found in microarray, which in turn 
lowered their confidence in explaining the results to patients. Counselors have reported being  
more comfortable with an expert physician providing the results and/or being willing to confer 
with them on results.24 For example, in a study by Bernhardt et al (2014), one genetic counselor 
stated: “I guess what helps me is that there’s somebody else saying the same thing I am and for 
patients like reinforcing the same information or lack thereof, is I guess can be helpful for them 
to at least accept the results”.24  
As CMA has become more common in the prenatal setting, additional data has become 
available and counselors have become more comfortable with unique aspects of the counseling 
process created by this testing. Genetic counselor response and adaptation to this testing may 
help to predict and/or guide how genetic counselors will deal with the possible implementation 
of exome sequencing in the prenatal setting. 
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1.1.8 Clinician Response to Clinical Exome Sequencing 
The implementation of genome and exome sequencing in the pediatric and adult clinical settings 
brought with it a number of challenges to genetic counselors and other clinicians dealing with 
this testing. Genetic counselors’ views and experiences with the implementation of this testing 
were assessed in a 2014 study.25 Some of the challenges specifically expressed by pediatric 
genetic counselors after the implementation of WES in the clinic included billing issues, the 
lengthy and information-heavy consent process, and interpretation and disclosure of VUS results 
and incidental findings. These challenges may increase when considering exome in a prenatal 
setting.  Prenatal counselors, as well as counselors in other specialties such as cancer, expressed 
discomfort offering the testing to their patients due to lack of clinical utility.25  
Further response to the integration of exome sequencing in the clinic has centered 
specifically on the issue of incidental findings, already cited above as a major challenge in 
implementing this testing. Members of the American Academy of Pediatrics, Section on 
Bioethics and Section on Genetics and Birth Defects, were surveyed to assess their attitudes 
toward incidental findings following the implementation of WES in the clinic.26 Only 34.7% of 
Section on Bioethics members surveyed agreed with ACMG-proposed mandatory reporting 
guidelines (highlighted above in section 1.1.2), while 70.8% of Section on Genetics and Birth 
Defects members agreed with these guidelines. For both groups, roughly 30% of respondents felt 
that parents should not be allowed access to information on adult-onset conditions in their 
children. Of all respondents, 80% felt parents should have a right to refuse this information.26 As 
highlighted above, these issues will remain in the context of prenatal exome sequencing, and 
may, in fact, become larger areas of debate. It may, therefore, be beneficial to assess these issues 
with prenatal providers as well. 
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1.1.9 The Utility of Prenatal Exome Sequencing  
While prenatal exome sequencing has only recently been made available to clinicians, many 
commercial laboratories do offer exome sequencing on fetal demise samples. In addition, some 
research studies have been done on the efficacy of exome sequencing in the prenatal setting. 
A study conducted in 2014 sought to demonstrate the utility of exome sequencing in the 
prenatal setting by analyzing 30 parent-fetus trios in which the fetus had at least one structural 
anomaly on ultrasound.27 This study showed a diagnostic yield of 10%, finding 3 de novo 
variants likely to be pathogenic. The study found an additional 5 variants (17%) in “plausible 
candidate genes” that were de novo, inherited recessive, or X-linked, which required further 
validation to determine pathogenicity. A 10% diagnostic yield is relatively comparable to the 
diagnostic yield associated with CMA and karyotyping in the presence of fetal ultrasound 
anomalies and lends some credence to the idea that exome sequencing would be clinically useful 
in a prenatal setting.27  
A second study conducted by a commercial laboratory analyzed 7 fetal demise samples 
using whole exome sequencing.28 Six of these fetuses were from couples who had experienced 
more than one affected pregnancy. All 7 fetuses had normal karyotypes, and 5 of the 7 fetuses 
had normal or inconclusive CMA results. After WES analysis, 4 of the 7 fetuses were found to 
have a relevant alteration (pathogenic or likely pathogenic variants): a diagnostic yield of 57%.28  
While these studies highlight the fact that WES can be clinically useful in a prenatal 
setting, especially when considering risk recurrence information for parents, a major drawback of 
both studies is the small sample size, which likely inflates the actual diagnostic yield. Further 
studies utilizing larger sample sizes will be important in determining a more accurate estimate of 
the diagnostic yield of prenatal WES. 
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1.1.10 Ethical Concerns for Prenatal Exome Sequencing 
Any testing in the prenatal setting can raise ethical concerns due to the sensitive nature of 
pregnancy and pregnancy management decisions. Many of the ethical concerns surrounding 
prenatal exome sequencing hinge significantly on the context in which it would be used. From a 
purely technological standpoint, it is possible to use WES as a screening tool in the prenatal 
population. The argument for using this testing as a screening tool is that it could identify fully 
penetrant disorders that would likely result in a miscarriage or early death much earlier than 
ultrasound findings or later pediatric testing could, allowing for early termination of the 
pregnancy when it may be emotionally easier for the couple making the decision.29 However, 
WES as a screening tool could create significant challenges, given the large amount of 
information returned from WES, the high probability of VUS findings, the limited phenotypic 
information available for prenatal patients, and the likelihood of returning a mutation result for a 
gene that may cause a devastating phenotype, but has incomplete penetrance.29 
Even in the context of a prenatal case with clear ultrasound findings and negative or 
inconclusive diagnostic testing, ethical issues still arise. Many question whether or not incidental 
findings should be returned with a prenatal WES test result. There exists some question as to 
whether or not it would be ethically acceptable to provide information on adult-onset conditions 
for a fetus. Some argue that if these genes can be screened for using pre-implantation genetic 
diagnosis (PGD), returning the same result as an incidental finding is not significantly different. 
Others argue that testing for certain adult-onset conditions, such as most cancer genes, is not 
availably prenatally from many laboratories who offer this testing (excluding PGD). Because this 
testing would not normally be an option in prenatal diagnosis, the argument is that these results 
should therefore, not be returned as an incidental finding. In addition, an incidental finding for an 
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inherited dominant condition in a fetus would have implications for one of the parents, which can 
be emotionally difficult on its own without the additional stress of an affected pregnancy.29 For 
example, if a BRCA2 mutation were identified as an incidental finding in a fetus, this would have 
potentially immediate risk implications for the mother if the mutation had been inherited from 
her. 
The possibility for VUS results also warrants some ethical consideration. While there 
already exists the possibility for VUS results with prenatal CMA, the argument can be made that 
it is unethical to offer prenatal exome sequencing due to the high likelihood of a VUS result with 
a test that has such a broad scope. Variant interpretation relies heavily on phenotypic correlation 
which is limited or impossible when considering fetal sequencing. As such, the likelihood of a 
VUS result may be even higher with prenatal WES than it would be in a pediatric or adult 
setting. Uncertainty may be especially distressing in the context of a pregnancy and pregnancy 
management decisions.29 In addition, depending on the education level and level of concern of 
the couple undergoing sequencing, some couples may consider terminating based on a VUS that 
may have no real implication for the pregnancy or for the child’s health. This can be difficult for 
couples to deal with on a personal level, and could potentially draw backlash from those who are 
opposed to termination on broader scale. 
Even in the context of “definitive” pathogenic variant findings, there can be ambiguity. 
Many of the genes and pathogenic variants therein that we consider “fully penetrant” have never 
been identified prenatally before and, therefore, we do not know how these variants actually 
present prenatally in terms of phenotype. There are also many disorders for which penetrance 
and expressivity are highly variable, making it difficult to truly interpret the results when 
ultrasound can only provide a limited phenotype. This can again lead to termination based on 
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results which may never manifest in the childhood period, or which may vary drastically in 
severity from person to person. 
1.1.11 Patient Views of Exome Sequencing 
While it is important to consider technical and ethical issues surrounding prenatal WES, as well 
as to consider how genetic counselors have dealt with similar testing in the past, it is just as 
important to take into account how patients feel about this testing, including its many possible 
results and how they will utilize these results. To that end, several studies have been conducted 
to assess patient views of exome sequencing in general as well as prenatal exome specifically.  
A 2012 study carried out by the NIH ClinSeq project assessed preferences toward return 
of results from whole-genome sequencing.30 The majority of individuals surveyed wished to 
know their results for preventative means, with roughly 1/3 of respondents citing a desire to 
inform their family of their risks. Participants in the survey were able to distinguish between 
different categories of results and showed a preference for clinically actionable results over 
receipt of variants of uncertain significance. Overall, respondents felt they would value the 
information provided, and that it would empower them to make decisions about their healthcare. 
While patient desire to have this information does not automatically mean it should be offered to 
them, their willingness and ability to participate in the process of this testing is valuable to 
understand before testing is implemented.30 
In addition to being willing and interested to receive their genomic information, many 
patients are willing to share the results they receive with both their healthcare providers as well 
as family members who may be at similar risks.31 A 2015 study conducted on 29 participants 
who received results from the ClinSeq study showed that 72% of these participants shared their 
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result with at least one healthcare provider, with 31% reporting that the healthcare they received 
changed in response to this information. In addition, 93% of respondents shared their result with 
at least one family member. This is directly in line with responses from the aforementioned 2012 
study and illustrates that not only are patients interested in receiving genomic information, but 
they do utilize the information the majority of the time.31 
While these studies are useful in predicting general response to genomic information, it is 
important to further explore parental opinions specifically. Pediatric patients are the primary 
population clinically receiving exome sequencing, and therefore parents are the ones utilizing 
this information (and will be the patients utilizing the information in a prenatal setting).  
A 2016 study assessed parental views of WES in the setting of undiagnosed pediatric 
disorders by interviewing 19 parents of children who had undergone WES.32 Of the parents 
surveyed, 14 of 19 had child with a definite, likely, or possible diagnosis while the remaining 5 
had no diagnosis. Parents understood and were able to communicate their child’s WES findings 
and recurrence risks to family members and healthcare providers. A major concern of many 
parents was that a lethal disorder would be identified, but most parents said the hope of a 
diagnosis outweighed this concern. Those whose children had diagnoses said they felt their 
child’s healthcare was more focused and there was less worry surrounding medical visits. A 
source of frustration for those whose children had a rare disorder was the limited information 
available due to the general lack of data on such disorders. This study highlights the realities that 
parents face in the wake of WES results. Such results could be provided from prenatal exome 
sequencing as well, and so it is important to understand and prepare for the issues parents 
undergoing prenatal WES may face.32 
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When considering patient opinions on WES, it is important to consider how they might 
feel about the possibility of prenatal WES. A study conducted in 2015 sought to assess parental 
views on prenatal exome sequencing.33 Responding to a questionnaire while waiting for routine 
prenatal care, 83% of parents stated that they thought prenatal WES should be offered to 
patients. Thirty-four percent of parents said they would want WES for their pregnancy even if 
there was no indication for such testing. When asked about the return of results from WES, the 
majority of parents said they would want results related to both treatable and non-treatable 
childhood-onset conditions, both treatable and non-treatable adult onset conditions, and that 
results would likely influence future family planning decisions.33 It is important to recognize 
patient willingness to receive and utilize this information, and again points to the importance 
genetic counselors will play in adequately explaining the risks, benefits, and limitations of this 
testing to their patients. 
1.2 SPECIFIC AIMS 
1.2.1 Specific Aim 1 
Conduct an anonymized survey of approximately 200 genetic counselors with prenatal clinical 
and/or laboratory experience (both academic and commercial laboratories) to ascertain 
perceptions of different scenarios in which prenatal exome sequencing might be ordered or that 
might arise as a result of prenatal exome sequencing. 
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1.2.2 Specific Aim 2 
From survey responses, determine what the prevailing opinions towards prenatal exome 
sequencing are and what, if any, discrepancies exist between prenatal clinical counselors and 
laboratory counselors regarding opinions and beliefs towards prenatal exome sequencing. 
1.2.3 Specific Aim 3 
From survey responses, elicit comfort levels of prenatal clinical counselors with various aspects 
of prenatal exome sequencing and identify areas of need to be addressed before implementation 
of this testing. 
1.3 SIGNIFICANCE 
1.3.1 Specific Aim 1 
No study available in the literature has yet been done to determine genetic counselors’ views 
and/or opinions on prenatal exome sequencing. Therefore, the results of this project will fill a 
gap in the existing research. 
1.3.2 Specific Aim 2 
Understanding the opinions toward prenatal exome sequencing can help to gauge what the 
response might be should this testing become widely available to clinicians. In addition, 
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determining whether or not a discrepancy exists between laboratory counselors and clinical 
counselors may help facilitate discussion and implementation policy, as the laboratories play a 
significant role in deciding whether or not to offer this testing to clinicians. 
1.3.3 Specific Aim 3 
It is important to understand which aspects of prenatal exome sequencing, if any, genetic 
counselors are uncomfortable with, and to address these issues before implementation of testing. 
In addition, identifying areas of need is necessary to determine possible resources that could be 
made available to genetic counselors to enhance their comfort utilizing this technology in a 
prenatal setting. Because prenatal and laboratory counselors will be at the front line of this 
testing implementation, it is most important to gauge their needs and concerns. 
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2.0  MATERIALS AND METHODS 
This study was approved as an institutional review board (IRB) exempt study by the University 
of Pittsburgh IRB. (PRO15080297) (Appendix B) 
2.1 SURVEY DESIGN 
The study survey was a new design that utilized previous surveys on exome sequencing and 
prenatal CMA as a reference.24,25,34 Prior to its implementation, the survey was reviewed 
multiple times by members of the thesis committee, which includes licensed certified genetic 
counselors, a research human geneticist with expertise in statistical genetics, and a clinical 
geneticist. The survey was also piloted by several licensed and certified prenatal and laboratory 
genetic counselors, who provided feedback on the structure and utility of questions asked. The 
survey was designed using Qualtrics survey system through the My Pitt student portal. Inclusion 
criteria for the survey involved currently working as either a laboratory genetic counselor, a 
clinical prenatal counselor, or both. This inclusion criteria was chosen because these counselors 
will be the first to deal with implementation of prenatal exome sequencing. The survey included 
a list of terms that were used in the survey with explanations of these terms: whole exome 
sequencing, targeted exome sequencing, and incidental findings. The survey included questions 
to delineate laboratory genetic counselors from prenatal clinical genetic counselors. Two 
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questions assessed how much time previous or current prenatal clinical counselors spend on 
average preparing for and seeing patients. Survey questions assessed general comfort levels 
toward prenatal exome sequencing being offered under different circumstances by using a 
Likert-scale where 1 was equivalent to “strongly disagree” and 5 was equivalent to “strongly 
agree”. A subset of questions were shown only to individuals currently practicing as prenatal 
clinicians assessing their comfort level with counseling on various aspects of exome in a prenatal 
setting, assessed on the same Likert scale. Additional questions assessed opinions on incidental 
findings and targeted exome in a prenatal setting, and what resources would influence a 
counselor to be more supportive of the implementation of this testing. An open-ended question 
allowed participants an opportunity to explain what influenced their opinions on prenatal exome 
sequencing. The survey was designed to be anonymous, with no questions revealing identifying 
information which could be tied back to the participant. A copy of the survey in its entirety is 
included in Appendix A. 
2.2 SURVEY DISTRIBUTION 
Surveys were distributed to prenatal and laboratory counselors through the National Society of 
Genetic Counselors (NSGC) student research survey program. Through this service, members of 
NSGC received an e-mail with a description of the survey, inclusion criteria, and a link to the 
Qualtrics survey system. An e-mail informing members of the survey was sent on September 3, 
2015 with a follow-up reminder e-mail on November 5, 2015. Anyone with an NSGC 
membership had access to the survey. The survey remained open from September 3, 2015 until 
November 27, 2015. Please see Appendix A for the cover letter and survey content. 
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2.3 DATA ANALYSIS 
Descriptive statistical analysis was completed for all questions on the survey using the Qualtrics 
system. Participants who did not qualify (genetic counselors not working in either a laboratory or 
prenatal clinical setting) and participants who did not complete the entire survey were excluded 
from analysis. Question 19 allowed for open responses that required coding to group the 
responses into themes. Responses to this question were read through twice to identify common 
themes. Some responses touched on several themes. Using these themes, responses were then 
coded into categories such as: more education is required, time available for sessions, ability of 
patients to understand material, existing technology is sufficient, limitations of existing 
technology, targeted exome would be useful in a prenatal setting, targeted exome would not be 
useful in a prenatal setting, personal/ethical beliefs, clinical utility, VUS/Incidental finding 
concerns, family planning, and insurance/costs. Some of these categories fit into existing themes 
provided in the previous question, while some were uniquely identified themes. Coding was 
done by corresponding colors to the different categories and highlighting sections of the 
responses that fit these categories and then tallying how many responses fell into each category. 
If any individual respondent had expanded upon a theme that they also noted in the previous 
question, the open-ended response was not included in the tally as it was already accounted for in 
the previous question. 
Following descriptive analysis, responses were compared between different subgroups 
using the Mann-Whitney-Wilcoxon nonparametric test of statistical significance. The responses 
of laboratory counselors were compared to those of prenatal clinical counselors. In addition, the 
responses of counselors who have been working 5 years or less were compared to those who 
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have been working for more than 5 years. All nonparametric analysis was done using MiniTab 
Express statistical analysis software. 
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3.0  RESULTS 
3.1 DEMOGRAPHICS 
A total of 219 genetic counselors responded to the survey. Of these 219 respondents, 48 did not 
complete the survey and their answers were excluded from statistical analysis. An additional 11 
respondents did not qualify for the survey as they were not currently working in either a 
laboratory or prenatal clinical setting. These respondents were redirected to the end of the 
survey. One hundred and sixty total responses were evaluated for descriptive statistics and 
nonparametric analysis. Table 1 describes the current specialty in which these respondents were 
working. There were approximately equal numbers of laboratory and clinical prenatal counselors 
represented. 
 
Table 1. Current Specialty of Respondents 
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Table 2 describes the demographic information for the 160 respondents who met the 
study criteria and completed the survey. The majority of respondents were female (96.25%), ages 
25-34 (59.75%), and had been working in the field of genetic counseling for 1-5 years (36.48%). 
Respondents had experience in a variety of fields, with 73.42% having worked in prenatal clinic 
at some point in time. Of those genetic counselors who had experience in a prenatal clinic, 
59.66% said that an average prenatal session lasted between 30-40 minutes. 
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Table 2. Demographic Breakdown of Survey Respondents 
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3.2 RESPONSES TO PRENATAL WES AND TES 
The majority of respondents had never ordered whole exome sequencing for a patient (74.38%). 
Additionally, most respondents had never analyzed exome sequencing in a laboratory setting 
(79.38%). Questions focusing specifically on targeted exome sequencing revealed 88.75% of 
respondents had never ordered TES in a clinical setting and 90.63% of respondents had never 
analyzed TES in a laboratory setting.  
Table 3 describes the breakdown of responses to a series of Likert questionnaire items 
regarding counselor comfort levels for prenatal WES and TES in a variety of different situations. 
For each response, a value of 1 was equal to “strongly disagree”, 3 was equal to “neutral”, and 5 
was equal to “strongly agree”. For prenatal WES, the majority of counselors (59.4%) were 
comfortable with prenatal exome being offered after other diagnostic testing had been returned 
either negative or inconclusive. However, when presented with the option of prenatal exome 
being offered as a first-line diagnostic test, the majority of respondents (81.3%) were not 
comfortable with this scenario. This was also the only scenario for which no respondent strongly 
agreed that prenatal exome should be offered. Most counselors (59.4%) were comfortable with 
using prenatal exome to provide a genetic diagnosis for neonatal management decisions rather 
than pregnancy management decisions. Most respondents (78.8%) were opposed to allowing 
prenatal exome sequencing solely based on patient desire to have the testing. T 
For prenatal TES, the majority of genetic counselors were comfortable with TES being 
offered after other diagnostic testing had returned negative or inconclusive (74.4%) and in cases 
where TES was being used for neonatal, rather than pregnancy, management decisions (64.4%). 
In contrast, the majority of genetic counselors were not comfortable with TES being provided as 
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a first-line diagnostic test (68.8%) or solely when a patient expressed interest in having the 
testing (71.3%).  
 
 
Table 3. Genetic Counselor Comfort Levels with Various Prenatal WES/TES Scenarios 
 
 
The next series of questions related specifically to counseling situations related to 
prenatal WES and TES. These questions were only shown to individuals who answered that they 
currently work in a prenatal setting because they involved counseling scenarios that a laboratory 
counselor would not typically encounter. Table 4 describes the responses to these Likert 
questionnaire items. 
In regards to prenatal WES, just over half of prenatal clinical counselors were 
comfortable with most of the scenarios provided. Specifically, 56.3% of counselors were 
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comfortable providing pre-test counseling for prenatal WES. Additionally, 52.9% of respondents 
felt they would be comfortable disclosing and explaining VUS results, 44.2% were comfortable 
helping a patient to make pregnancy management decisions based on results from a prenatal 
exome, and 59.7% would be comfortable locating resources specific for their patient’s results. It 
is important to note that while the majority of respondents were comfortable or neutral regarding 
these situations, a sizeable number of counselors still responded that they would not be 
comfortable in these scenarios. Anywhere from 25-34% of counselors were uncomfortable with 
each given counseling scenario. 
When posed with the same counseling scenarios provided for prenatal WES, this time in 
the context of prenatal TES, genetic counselors were similarly mostly comfortable with each of 
the scenarios. When asked about comfort levels providing pre-test counseling for prenatal TES, 
80.5% of counselors were comfortable doing so. Additionally, 60.9% of counselors were 
comfortable disclosing VUS results from targeted prenatal exome sequencing. In regards to 
helping patients with pregnancy management decisions based on the results of prenatal TES, 
57.5% of respondents felt comfortable with doing so. Finally, 59.8% of respondents felt 
comfortable locating resources for patients based on results from prenatal TES. It is again 
important to note that this still leaves a considerable number of counselors who were not 
comfortable with such scenarios. Anywhere from 18-22% of counselors were uncomfortable 
with each given counseling scenario. 
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Table 4. Prenatal Clinical Counselors’ Comfort Levels with Prenatal WES/TES in Various Counseling Scenarios 
 
3.3 COMPARISON OF RESPONSES TO PRENATAL WES AND TES 
The responses for prenatal WES were compared to those for prenatal TES using the Mann-
Whitney test of statistical significance. For the scenario in which exome was used as a diagnostic 
test after other testing options had been exhausted, there was a statistically significant difference 
in responses, with a more favorable response to using TES in this situation (p=0.0088). In 
addition, there was a statistically significant difference in responses toward using prenatal exome 
as a first-line diagnostic test (p=0.0013), with counselors being more comfortable with this 
situation if TES were to be offered rather than WES, though responses favored disagreement 
with the use of this testing in such a situation. There was no statistically significant difference in 
responses for the remaining two scenarios given. For counseling scenarios, there was no 
statistically significant difference in genetic counselor comfort levels between prenatal WES and 
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TES, except for the scenario of providing pre-test counseling. For this scenario, there was a 
statistically significant difference in responses (p=0.0012), with counselors being more 
comfortable providing pre-test counseling for TES than WES. 
3.4 RESPONSES TO INCIDENTAL FINDINGS 
The next sets of questions dealt with types of incidental findings that could be reported and 
counseling scenarios surrounding return of incidental findings. As above, counseling scenario 
questions were only provided to individuals who responded as currently working in a prenatal 
clinical setting. Table 5 and Table 6 describe the responses to these questions.  
The majority of respondents (55.6%) believed that incidental findings from the ACMG 
minimum list should be reported in prenatal exome sequencing cases. In addition, 77.5% of 
counselors also felt that incidental findings for childhood-onset conditions should be reported. 
Responses differed in regards to other categories of incidental findings results. Results were split 
almost evenly for the report of hereditary cancer genes, with 31.9% of respondents against 
reporting these results, 36.2% neutral, and another 31.9% in favor of reporting. Most respondents 
were against reporting incidental findings that revealed carrier status (43.8%) and those related to 
adult-onset conditions (55.6%). Nearly half of all respondents (49.4%) felt comfortable allowing 
patients to choose freely from any of the listed categories, while 16.9% were neutral, and 33.7% 
were not comfortable with this scenario. 
Most prenatal clinical counselors (72.4%) responded that they would be comfortable 
discussing incidental findings in pre-test counseling sessions. Comfort levels were less 
consistently favorable for the other scenarios provided. While many of the respondents were 
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comfortable (43.6%) or neutral (33.3%) regarding disclosing incidental findings results, only 
37.9% were comfortable helping a patient making pregnancy management decisions based on 
these types of results while 43.6% were not comfortable with this scenario. Regarding locating 
resources based on the results of incidental findings, 49.4% of counselors felt comfortable doing 
so, while 30.6% were not comfortable. 
 
 
Table 5. Genetic Counselor Comfort Levels with Various Categories of Incidental Findings  
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Table 6. Prenatal Clinical Counselors’ Comfort Levels with Various Counseling Scenarios Related to 
Incidental Findings from Prenatal WES 
3.5 RESPONSES TO SUMMARY QUESTIONS 
Respondents were asked if they would support prenatal exome sequencing being offered by 
genetic testing laboratories. These responses are highlighted in Figure 1. Most respondents 
stated that they would support labs offering this testing in one of two restricted situations: only if 
it was restricted to cases with a clear clinical indication (46.9%) or only if it was limited to a 
phenotype-drive targeted exome (31.9%). An additional 13.1% of respondents would support 
prenatal exome sequencing in any scenario. Only 8.1% of respondents would not support 
prenatal exome in any situation. 
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Figure 1. Genetic Counselor Preferences for Laboratories Offering Prenatal Exome Sequencing 
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As shown in Table 7, the majority of respondents reported understanding the clinical 
utility of exome sequencing in general (95.0%) and felt that it could be clinically useful in a 
prenatal setting (68.2%). Responses regarding whether or not commercial laboratories should 
offer this testing to their clients were somewhat divided, with 28.7% disagreeing with this 
scenario, 34.4% neutral, and 36.9% responding positively. The majority of counselors (69.4%) 
were more comfortable with the idea of prenatal microarray than they were with prenatal exome. 
Approximately 50% of respondents stated that they would be more comfortable supporting 
prenatal exome sequencing if a medical geneticist was there to provide the results with them, 
while 23.8% were neutral and the remaining 26.2% disagreed that this scenario would make 
them more comfortable supporting this testing. The majority of respondents (70.7%) were more 
comfortable supporting prenatal exome sequencing if educational or training opportunities could 
be made available to them prior to implementation of this testing in a prenatal setting.  
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Table 7. Genetic Counselors’ Understanding of Prenatal Exome and Areas of Need  
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3.6 FACTORS INFLUENCING RESPONSES 
For the final component of the survey, participants were given a “check all that apply” option for 
factors that influenced their decisions, and support of, prenatal exome sequencing. They were 
then allowed an open-ended question for any additional factors they felt were not covered on the 
supplied list. Fifty-four genetic counselors provided responses to the open-ended question. Based 
on themes from responses to this question, the responses were coded into the existing categories 
listed in the prior question, as well as a few additional categories not covered.  
Several themes emerged that were not previously identified in the “check all that apply” 
question. One of the biggest concerns stemmed around dealing with VUS and incidental findings 
results (n=11). One respondent said,  
“My main concern about offering whole exome prenatally would be the possibility of 
identifying variants of uncertain significance, and what that would mean for pregnancy 
management and counseling. Additionally, ACMG secondary findings that are related to 
cancer/adult onset conditions would have to be carefully considered and discussed with the 
patient.” (Laboratory Counselor) 
Along the same lines, another respondent discussed the difficulty incidental findings 
might create in the counseling process:  
 37 
“A thought that crossed my mind while answering this survey was that if we offer PGD 
for something (essentially offering the patient a "way out," if you will), then is it really fair that 
we wouldn't disclose results of a same caliber from exome sequencing?  I mean, I'm definitely 
uncomfortable with thinking about disclosing BRCA results from a prenatal exome, but when 
thinking about what should be included on a report, I'm a little torn.” (Clinical Prenatal 
Counselor) 
Other responses focused on variants in the context of technological limitation, with 8 of 
the 54 respondents who answered the open-ended question citing that they felt there would be 
too much uncertainty around variants, and limited ability to gather fetal phenotype to aid in 
variant interpretation with current technological capabilities.  
“All my experience with WES has been in the pediatric setting. Results are not always 
definitive. We receive lots of likely pathogenic result. We frequently use the results to explain 
the phenotype we observe. In the prenatal settings we fear that we could receive lots of results 
with unclear clinical significance and this will cause additional stress and anxiety for the 
pregnant woman...” (Clinical Prenatal Counselor) 
Another factor affecting opinions on prenatal exome identified through the open-ended 
question was the need for further education before testing is implemented (n=6), not just for 
genetic counselors, but for any prenatal provider who might be involved in the process. As one 
genetic counselor said: 
“There needs to be a lot more education offered for genetic counselors and medical 
professionals about the clinical utility of exome sequencing. I hear other medical professionals 
(outside of genetics) discussing how great exome sequencing would be and I feel that they don't 
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really understand the type of information their patients may receive from these results.” (Clinical 
Prenatal Counselor) 
 
 
Another respondent echoed and elaborated upon these sentiments: 
“In addition to having concern about patients' ability to handle the amount of 
information, I have concern about the ability of many physicians to understand, interpret, and 
communicate results with patients and have had experience in prenatal clinics where the OBs did 
not understand information about Fragile X carrier test results, NIPT testing, or testing for 
recessive conditions and these seem like they should be "basic" concepts for physicians from 
different backgrounds (especially OBs), not just geneticists.” (Laboratory Counselor) 
Issues surrounding TES and its utility emerged as well. More respondents felt that the 
technology would be useful, and perhaps even preferable, to WES in a prenatal setting (n=3). 
“Targeted exome in prenatal is the only appropriate option. All adult onset and hereditary 
cancer syndromes should be excluded.” (Clinical Prenatal Counselor) 
“…targeted exome seems more appropriate, although I think diseases we could test for 
would be fairly limited based on U/S findings” (Laboratory Counselor) 
“The idea of a targeted WES is appealing and would reduce the risk of incidental findings 
(such as WES for skeletal dysplasias as multiple gene panels are very expensive)” (Clinical 
Prenatal Counselor) 
One respondent, however, felt the TES had even less utility in the prenatal setting than 
WES: 
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“I also don't feel that "targeted" or "phenotype-driven" exome sequencing is useful. 
Analyzing only known disease genes would potentially miss causative novel disease genes that 
could be identified in trio based whole exome sequencing. Furthermore, the effort/cost/time that 
goes into whole exome sequencing vs. targeted sequencing is negligible. I don't think targeted 
exome is useful in any circumstance actually.” (Laboratory Counselor) 
A final theme that emerged from the open-ended question was the importance that 
prenatal exome could play in discussions of family planning and recurrence risk (n=6), 
particularly in the setting of couples who had multiple similarly affected pregnancies. Several 
respondents had statements regarding the utility of prenatal exome for this purpose: 
“I think it's important to have this technology available for families who cannot get a 
prenatal diagnosis by other methods (microarray, sequencing panels, etc). It's important that 
families understand the causes for their baby's anomalies (and prognosis) and if there is expected 
to be an associated recurrence risk.” (Clinical Prenatal Counselor) 
“I think in the event that a patient has a fetus with multiple anomalies, with normal 
genetic testing (microarray and suspected single gene) an exome could be considered.  I think it 
could be useful in cases where a child may pass away shortly after birth and performing an 
exome prenatally would be the most efficient and cost effective way (if covered by insurance) to 
provide the family with a potential answer and RR.” (Clinical Prenatal Counselor) 
The responses were coded and categorized into themes. These themes were ultimately 
labeled as: more education required, targeted exome would not be clinically useful in a prenatal 
setting, targeted exome would be clinically useful in a prenatal setting, family planning for 
recurrence risk or termination, concerns about VUS and/or incidental findings results, and 
technological limitations (such as turnaround time or variant interpretation).   
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Other responses simply elaborated on themes from the “check all that apply” question 
and were therefore either added to the tally for those questions (if the participant had not checked 
the corresponding box), or not added to the tally (if the participant had already checked the 
corresponding box). The answers provided, while already related to factors in the “check all that 
apply” question, were nonetheless beneficial in highlighting why these factors influenced genetic 
counselors’ opinions. 
Tallied results to these questions are highlighted in Figure 2.  
Figure 2. Factors Influencing Genetic Counselors’ Opinions on Prenatal Exome Sequencing  
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The two factors most largely influencing respondents’ views on exome sequencing were 
the perceived ability of patients to handle the amount of information provided by the testing 
(n=125) and the clinical utility of exome sequencing in the prenatal setting (n=123). Many of the 
responses to the open-ended question elaborated on responses given in the prior question and 
how these items factored into individual opinions toward exome sequencing. 
Several answers to the open-ended question provided some clarification of how 
respondents felt about the perceived ability of patients to handle the amount of information 
provided by the testing. Some respondents felt that the amount of information would be too 
difficult to handle during an already stressful time: 
“I'm concerned about the amount of information that would be provided to parents at a 
time when they are particularly stressed. If incidental results were found, I would be concerned 
about parents getting that information while also trying to process the issues more immediately 
facing them during pregnancy that is abnormal in some way.” (Prenatal Clinical Counselor) 
Other respondents were concerned about a patient’s ability to fully comprehend results, 
especially uncertain ones: 
“I think a lot of patients would have a difficult time dealing with VUSes. I previously 
worked in the prenatal setting with very high-maintenance patients, who nit-picked every 
possibility. I could see those type of people grappling with terminating over VUSes or adult on-
set conditions.” (Laboratory Counselor) 
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Additionally, respondents had comments regarding the issue of clinical utility of exome 
sequencing. Some responses elaborated that there was limited utility to prenatal exome 
sequencing, while others argued that the utility was clear. One respondent arguing for its utility 
said: 
“I would be hesitant to offer this testing to all individuals in a prenatal clinic, but I do 
think exome sequencing is a clinically useful test that will be incorporated into our standard of 
care offerings. I think prenatal exome can be a useful tool but should be used with discretion. 
Patients need to be fully informed of the benefits and limitations and providers should be aware 
of the benefits and limitations.” (Clinical Prenatal Counselor) 
Another respondent argued that the utility of prenatal exome was not quite as clear: 
“I think the greatest utility of exome sequencing may actually be on POCs [parents of the 
child], to provide couples planning to have more children with recurrence risk information. With 
current technology, the actual utility prenatally to make a decision about the pregnancy seems 
limited. just because it is possible or available does not mean it is a good idea to implement it.” 
(Clinical Prenatal Counselor) 
3.7 COMPARISON OF PRENATAL CLINICAL COUNSELOR AND 
LABORATORY COUNSELOR RESPONSES 
When all descriptive analysis was complete, the responses of lab counselors were compared to 
those of clinical counselors using the Mann-Whitney test of statistical significance. For the 
purposes of analysis, individuals who identified as currently working in both lab and clinical 
positions were grouped with prenatal clinical counselors and included in the clinical responses. 
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Responses were significantly different for several questions. In regards to prenatal WES 
scenarios, there was a statistically significant difference for use of prenatal WES as a first-line 
diagnostic test (p=0.0016), in addition to use of prenatal WES as a means for guiding neonatal 
management (p=0.0236). For these scenarios, a larger number of laboratory counselors agreed 
that prenatal WES should be offered when compared to the number of clinical counselors 
favoring its use in these situations. There was no statistically significant difference in responses 
between groups for questions regarding the types of incidental findings that should be returned 
for prenatal WES. For scenarios involving prenatal TES, laboratory counselors were again more 
likely than clinical counselors to agree that this testing should be offered as a first-line diagnostic 
test (p=0.0214). There was no statistically significant difference in any other responses regarding 
prenatal TES.  
More laboratory counselors agreed that they understood the clinical utility of exome than 
clinical counselors (p < 0.0001), with 98.6% of lab counselors agreeing or strongly agreeing with 
this statement compared to 91.9% of clinical counselors. Regardless, there was not a statistically 
significant difference in whether or not these counselors felt exome sequencing could be 
clinically useful in a prenatal setting. Significantly more clinical counselors than laboratory 
counselors were more comfortable with the idea of prenatal microarray than prenatal exome 
sequencing (p=0.0003). There was no statistically significant difference found between these 
groups for any other responses in the survey. 
An additional analysis was conducted to determine if responses from counselors who had 
been working for less than 5 years were statistically different from those who had been working 
for 5 years or more. More counselors who had been working for less than 5 years agreed with the 
statement “I am more comfortable with the idea of prenatal microarray than prenatal exome” 
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(82.9%), while responses from counselors working for 5 years or more were more spread out, 
with the majority agreeing with the statement (58.3%) and the remaining 41.7% disagreeing or 
neutral. The difference in responses was statistically significant with a p value of 0.0014.  There 
was no statistically significant difference found for any other responses in the survey. 
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4.0  DISCUSSION 
4.1 ANALYSIS OF SURVEY RESPONSES 
Exome sequencing (WES and TES) is utilized in pediatric and adult settings and uptake into 
these settings occurred relatively soon after the testing became clinically available.25 Uptake of 
newer, more unfamiliar testing has traditionally taken longer to reach the prenatal setting, but 
using testing such as microarray as an example, it is expected that exome sequencing will be 
more widely offered in the prenatal setting in the near future, bringing with it several situations 
that complicate the genetic counseling process and patient understanding of results.25,29 This 
study helped to elucidate situations in which genetic counselors might be more or less inclined to 
offer prenatal WES or TES, comfort levels with various counseling issues that could arise as the 
result of prenatal WES or TES, areas that need to be addressed prior to testing implementation, 
and factors influencing these opinions. 
Despite the controversial nature of offering exome in a prenatal setting, the majority of 
genetic counselors (59.4%) were, at the very least, comfortable with prenatal exome as a last 
option diagnostic test for patients when other diagnostic testing was negative or inconclusive. 
Many counselors were also comfortable with the use of prenatal exome to guide neonatal 
management decisions (59.4%). Importantly, comfort levels were much lower for both prenatal 
WES and TES as a first-line diagnostic test or as an effective screening test (any time a patient 
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expresses interest in having the testing), indicating that genetic counselors have a clear 
preference for how and when the test is utilized in clinical settings. Discrepancies existed 
between laboratory and clinical counselors, with more laboratory counselors responding 
favorably to both WES and TES as a last option diagnostic test. This may be related to the fact 
that a significant difference (p < 0.0001) was observed in the number of respondents who agreed 
that they understood the clinical utility of exome sequencing, with more laboratory counselors 
also responding affirmatively to this question. However, this explanation is unlikely given that 
there was no significant difference observed between clinical and laboratory counselors’ 
opinions on whether or not this testing could be useful in a prenatal setting. It is possible that the 
difference could instead be explained by the fact that laboratory counselors would not have to 
deal with the complications this testing would create in the clinical setting, such as counseling on 
incidental findings and VUS results, and would primarily be dealing with analysis and variant 
interpretation, more positively coloring their views regarding the testing. It is also possible that 
laboratory counselors have implicit bias in regards to supporting newer forms of testing because 
laboratory revenue comes from implementing and marketing new testing. However, it is 
important to distinguish that this bias may differ even amongst laboratory counselors, as some 
work directly with sales while others have little or no stake in marketing and sales of tests.  
While definitions were given for whole exome sequencing, targeted exome sequencing, 
and incidental findings prior to respondents completing the survey, many prenatal clinical 
counselors responded that they had no experience ordering or utilizing exome sequencing. This 
may in turn account for discrepancies between laboratory and clinical counselors, as having more 
experience with, and understanding of, the technological aspects of exome sequencing may 
influence opinions and comfort levels with the testing. Regardless of the reasons for 
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discrepancies, it is important to note these differences, and that laboratories should consider 
these results when deciding when and how to offer testing to prenatal clinical genetic counselors 
and other prenatal clinicians. 
The majority of respondents (59.66%) who had worked in a prenatal setting before stated 
that their average prenatal session lasted 30-40 minutes. Existing literature has shown that the 
extensive informed consent process for WES and TES lengthens and complicates genetic 
counseling sessions.25 Consideration should be given to this discrepancy in time available to 
prenatal counselors. Counseling for prenatal exome may require multiple sessions, increasing the 
risk of losing patients to follow-up, in addition to the more obvious concern as to whether or not 
enough resources exist to take on this extra caseload.  
Most respondents were comfortable with offering childhood-onset and ACMG minimum 
list incidental findings genes and less comfortable with offering incidental findings for genes 
associated with carrier status, adult-onset conditions, and cancer genes. Congruent with the 
principle of autonomy, the majority of respondents still agreed that patients should have the 
option to choose freely from any of the categories, providing any incidental findings are returned 
on a prenatal exome. Many of the responses to the open-ended question elaborated that answers 
to the questions regarding incidental findings were not straightforward. Previous literature has 
shown that ethical concerns exist around more controversial incidental findings such as adult-
onset and cancer genes being returned in a prenatal setting.29 Answers highlighted in the results 
of this research echo previous discussions in the literature. In existing prenatal testing, it is 
generally considered acceptable to test for adult-onset disorders/cancer genes using pre-
implantation genetic diagnosis. In addition, in the current pediatric setting, individuals 
undergoing exome can still receive these incidental findings results. Therefore, some individuals 
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argue that incidental findings for adult-onset conditions should be returned in prenatal WES as 
well.29 Participant responses agreed with this consensus, but many respondents were still 
uncomfortable with the idea of returning, for instance, BRCA results from a fetal exome analysis. 
The option to return incidental findings with prenatal WES seemed to be an issue that generated 
some of the greatest concern for respondents. Clinical counselors were less comfortable with 
counseling scenarios regarding the return of incidental findings in this context than they were 
with the generalized counseling scenarios of returning exome results, including VUS results. 
Several respondents expressed concern about how parents might make pregnancy 
management decisions based on incidental findings unrelated to the fetus’ phenotype. A 
suggestion to avoid such a difficult scenario was provided by at least one respondent, “If the 
disclosure of incidental findings were agreed to be held off until after delivery (like 3-6 months), 
then I would be more agreeable to prenatal exome sequencing”. While this idea could alleviate 
some of the immediate difficulties surrounding prenatal exome sequencing and the counseling 
process, the onus of providing these results would still fall onto someone. It would then need to 
be decided if these results should be provided by the same counselor, a pediatric counselor, or 
another health care provider and would require patient follow-up for disclosure.  This may be 
even more challenging should the parents be dealing with a child with multiple medical needs. 
These results highlight the importance of careful consideration as to whether or not incidental 
findings should be offered at all and the process of disclosure. 
Differences in responses between prenatal WES and TES show a statistically significant 
preference for TES in this setting (p=0.0088), likely because it eliminates the likelihood of 
incidental findings and could potentially lower the likelihood of VUS results if the genes 
reviewed are limited to those related to the fetus’ phenotype. While some respondents argued 
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that utilizing TES as a replacement for, as an example, skeletal dysplasia panels could ultimately 
be faster and cheaper than ordering an actual skeletal dysplasia panel, others argued that the 
limited phenotypic information provided by ultrasound would render TES useless. A 
consideration could be made that TES would be the best way to first introduce exome 
sequencing to the prenatal setting to alleviate the burden of dealing with incidental findings and 
examine the efficacy of such a test. Most studies of exome’s efficacy have shown that the 
detection rate increases with the use of a trio.5,6 While utilizing TES in a prenatal setting would 
not exclude the use of a trio to determine gene segregation, there would still be the potential to 
miss novel gene findings and limited ability to utilize phenotypic information given by 
ultrasound. Use of a trio would also potentially add to turnaround time, which is already high for 
exome sequencing of any type, and is a greater concern in a prenatal setting where time is 
limited. In addition, all studies on the efficacy of exome in the prenatal setting have utilized 
WES. These studies are promising, but still only show a detection rate comparable to existing 
technology such as microarray.27,28 This detection rate would be more likely to decrease in the 
context of prenatal TES. It is therefore important for genetic counselors, both laboratory and 
clinical,  to consider the utility of both prenatal WES and TES when considering what they may 
offer to clients in the future, especially given that results of this study show a preference for TES 
on the part of respondents. 
A variety of responses affected genetic counselors’ opinions on prenatal exome 
sequencing suggesting these factors are areas that would be important to address before or during 
implementation of WES/TES in the prenatal setting. Major factors contributing to opinions 
included concerns over technological limitations (turn around time, ability to analyze and 
interpret variants, etc.), ability of patients to handle the amount of information provided by 
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testing, difficulty in properly counseling patients about prenatal exome sequencing, difficulty in 
dealing with insurance or billing issues, and clinical utility. Interestingly, while many of these 
factors are what caused counselors to be hesitant about utilizing prenatal exome, some 
counselors cited favorable responses toward clinical utility. Some of those who recognized that 
prenatal WES/TES had clinical utility still had reservations due to the limited phenotype 
provided in the setting. Many respondents indicated that the factors affecting their responses 
were significant and should be addressed before this test could be efficiently and usefully offered 
to patients.  As one respondent said,   
“I would love to be able to potentially provide them with a diagnosis so that we can offer 
more effective prenatal diagnostic testing rather than just fall back on saying there's a 25% 
recurrence risk for an unspecified disorder. I think there are several significant hurdles that need 
to be overcome before prenatal or targeted exome sequencing should reach the prime-time 
clinical setting.”  
 The factor, perceived ability of patients to handle the amount of information provided by 
exome sequencing, was cited by the most respondents as affecting their opinions and  
perceptions of prenatal WES/TES. Respondents expressed concern that some findings, including 
incidental findings, could have phenotypic uncertainty/variable penetrance. This could 
potentially be difficult for patients to understand or deal with because it becomes extremely 
challenging to predict how severely affected their child might be. As one respondent said: 
“The one concern is our limited knowledge of genetics.  I was at a meeting in which a 
leading edge researcher made a comment that on whole exome testing she was found to have a 
mutation for an autosomal dominant genetic condition that she clearly does not express.  So had 
her parents been given that result, they would have been told that she would have this very well 
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understood condition - but she doesn't have any symptoms of this condition at all…if patients 
terminate due to abnormal findings (a very common decision in my region) we won't know how 
many of those kids never express symptoms (like the researcher I mentioned).” (Clinical Prenatal 
Counselor) 
This echoes existing research by Bernhardt et al assessing counselor response to prenatal 
chromosomal microarray (CMA),24 in which counselors interviewed for the study discussed that 
the phenotypic uncertainty of some copy number variants caused significant distress for patients. 
One respondent in the Bernhardt study said this about the uncertainty: 
“It’s frustrating especially as this technology has taken off and there’s just not a lot of 
data about these esoteric deletions or duplications. All you can do is go to a family and say, 
“Well, we found a change, but there are only 3 cases in the literature and one’s walking around 
and fine and the other 2 have severe mental retardation.”24 
The results from this study builds upon previous research on CMA testing in the prenatal 
setting and supports the idea that a major concern among genetic counselors is the potential to 
encounter significant uncertainty with the test results. Uncertainty is complicated in the prenatal 
setting, as highlighted by the responses above, by the inability to accurately predict phenotype 
and provide parents with an accurate risk assessment for their unborn child.  
In another study by Machini et al (2014) assessing genetic counselors’ views and 
experiences with the integration of WES and whole genome sequencing into the clinical setting, 
respondents who did not offer WES after its implementation were asked to cite their reasons for 
not offering the testing. While the respondents to this survey were not limited to genetic 
counselors, clinical utility was one of the most cited reasons for not offering this testing.25 This is 
consistent with the data highlighted in the results section of this document, with 123/160 
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respondents citing clinical utility as a factor that influenced their opinions on prenatal WES/TES, 
the second most-cited answer after patient ability to understand results. Most of the responses in 
the open-ended question that elaborated on this issue focused on the uncertainty of a phenotype 
provided by ultrasound and how important it would be to have the information immediately 
rather than after the child was born. Nearly 50% of respondents to the Machini survey had not 
offered WES because of their area of practice, with prenatal clinicians making up only 20% of 
all respondents.25 It is perhaps unsurprising that these clinicians would find less clinical utility 
for WES than in the pediatric setting and interestingly, two years later, the data from this 
research suggests clinical utility is still a major factor influencing how prenatal genetic 
counselors feel about WES in this setting. Since the Machini paper was published, however, two 
separate studies have provided promising, if limited results on the clinical efficacy of WES in the 
prenatal setting.27,28 With these studies in mind, and as exome sequencing becomes a more 
commonly used test, it is interesting to note that 68.2% of respondents to this survey felt exome 
sequencing could be clinically useful in the prenatal setting. This suggests that perceptions about 
the clinical utility of exome in a prenatal setting may be gradually shifting. It is important to 
consider that while 123 respondents cited clinical utility as a factor influencing their opinions on 
prenatal WES/TES, these respondents include both those who felt negatively about the clinically 
utility of prenatal WES/TES as well as those who felt positively.  
Some of the additional factors complicating the integration of WES into the clinical 
setting in the Machini study were the same factors that influenced opinions of prenatal WES in 
this study. These included insurance/billing issues, results interpretation (here grouped with 
technological limitations), and turn-around time.25 Both studies highlighted a need for further 
training to assist in a more seamless integration of exome sequencing in the clinic. It is important 
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to note that problems surrounding exome sequencing highlighted 2-3 years ago are still concerns 
genetic counselors have about this testing and that these issues could be amplified in the prenatal 
setting. It may be more difficult for insurance to cover such novel testing with a limited 
phenotype to warrant the testing in a prenatal setting, and along those lines limited phenotype 
hinders the ability of laboratories and genetic counselors to interpret results. While turn-around 
time for exome sequencing has been reduced since its implementation, it may still take months to 
receive results once insurance is approved, which, as stated with discussion of trio testing above, 
may even be more critical when pregnancy management decisions are being made. 
It is important to also consider prenatal clinical counselors’ comfort levels with scenarios 
that would arise as a result of prenatal exome sequencing. No studies were identified that 
assessed counselor response to prenatal exome, but responses of this research can be  compared 
to existing research on counselor response to prenatal chromosomal microarray (CMA) as well 
as the integration of exome/genome sequencing into the pediatric and adult clinics. In a 2014 
study by Bernhardt et al assessing genetic counselors’ perceptions and experiences with CMA in 
the prenatal setting,24 60% of respondents were comfortable with counseling on uncertain results 
that could result from a microarray.24 The data from the research highlighted in the results 
section of this document suggests that, regardless of the test being discussed, comparable 
amounts of counselors, when compared to the results of the Bernhardt study, feel comfortable 
counseling in such situations, with 52.9% of respondents to this survey citing that they would be 
comfortable counseling on uncertain results for a prenatal exome. Interestingly, similar numbers 
of respondents expressed that they would be comfortable helping a patient make pregnancy 
management decisions. In the 2014 Bernhardt study, only 43% of respondents were comfortable 
with such a situation in the context of uncertain CMA results24, comparable to the 44.2% of 
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respondents who were comfortable with helping patients to make pregnancy management 
decisions based on any results of prenatal exome sequencing. While the question in the 
Bernhardt study specifically addressed uncertain results, the comparable numbers could indicate 
that there is, in general, more uncertainty around exome in the prenatal setting, which would 
cause fewer genetic counselors to be comfortable assisting the pregnancy management decisions 
of patients. This is especially likely when consideration is given to the fact that 80% of 
respondents in the Bernhardt study were comfortable helping patients to make pregnancy 
management decisions in the context of a clearly abnormal CMA results,24 much higher than the 
44.2% who were comfortable with the same scenario in the context of prenatal exome. This 
discrepancy may also be attributed to the fact that this study was conducted prior to 
implementation of WES/TES in the prenatal setting, therefore few prenatal counselors have had 
access to such testing and its results in order to become comfortable with these scenarios, while 
the Bernhardt study was conducted following implementation of CMA in the prenatal setting. 
The factors stated as affecting opinions in this research, and the number of counselors citing 
these factors, are items that could be considered prior to introducing this testing in the clinic.  
While most respondents were comfortable with all counseling scenarios given for both 
WES and TES, significant numbers of respondents still expressed discomfort with these 
scenarios. While genetic counselors may always have some level of discomfort with difficult 
scenarios such as counseling on VUS results in a prenatal setting, it is worthwhile to address this 
discomfort and provide tools and resources which may increase the number of counselors who 
are comfortable with these situations. Over 70% of respondents stated that they would be more 
likely to support prenatal exome if educational resources were provided before its 
implementation. This is congruent with existing literature assessing prenatal counselors’ 
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responses to the introduction of CMA to this setting.24 The study by Bernhardt et al (2014) 
addressed specific areas of education or training related to prenatal CMA and gauged how many 
respondents would be interested in such training. More than 80% of respondents in that study 
were interested in receiving further education on locating resources for up-to-date information on 
specific test results, dealing with uncertain results, and communicating abnormal or uncertain 
results to patients.24  
These are scenarios identified as major areas of concern for prenatal exome as well. 
Perhaps, priority could be given to the factors that the majority of respondents cited. Because 
genetic counselors will likely be the first line of prenatal providers offering this testing, efforts 
could be made to utilize this information to identify and address areas of concern to best ease the 
process of introducing WES/TES to the prenatal setting. This effort could fall under the purview 
of either the organizations responsible for the education and training of genetic counselors and/or 
the laboratories seeking to offer this testing to their clients. Many genetic testing laboratories 
already offer such resources, either in the form of client and patient pamphlets for panel tests, or 
in the form of field specialists, i.e. genetic counselors who help to educate their clients about new 
testing. If laboratories wish to begin offering this testing, it may be in their best interest to 
provide this education (as more educated clients may be more likely to utilize the testing), but it 
is also in the patient’s best interests, as a more educated clinical provider may be more 
comfortable and confident in the information they provide to their patient as well as in 
identifying when this testing is appropriate to offer.  
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4.2 LIMITATIONS AND FUTURE RESEARCH 
One limitation to this study was the fact that demographic information was provided at the end of 
the survey, limiting the ability to determine if there were any significant factors affecting 
participation and completion of the survey. This decision was made to address the concern that 
demographic questions may ‘prime’ participants to respond according to a certain identity. 
Ultimately, those who did not complete the survey were excluded entirely from analysis. 
Because these participants did not reach the end of the survey, they did not complete the 
demographic questions and no analysis could be done on these individuals.  
While 160 responses provided useful data and is a significant response rate for a field the 
size of genetic counseling, it by no means encompasses the entire population of prenatal and 
laboratory genetic counselors in North America. There may be many genetic counselors with 
significantly different opinions and responses not represented by this survey, which is a 
limitation created by any questionnaire-based research as data is limited to individuals who 
decide to take the time to participate and respond. Prenatal clinical counselors make up 
approximately 35% of all clinical counselors, while laboratory counselors make up roughly 26% 
of all non-clinical counselors, indicating that there are hundreds of genetic counselors whose 
opinions are not accounted for in this survey.35 
While Likert-scale questions are validated as research tools, this specific survey is new 
and therefore has not been validated as a research tool. Some questions of the survey may have 
been ambiguous, which in turn may have altered the responses to these questions. One such 
example is the question “I would like commercial laboratories to make this testing available to 
clients”. In this question, “clients” was meant to refer to genetic counselors and physicians who 
order testing from commercial laboratories. However, it is possible that clinical genetic 
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counselors interpreted “clients” to mean patients and therefore thought that the question was 
asking whether or not they would effectively support labs offering this testing in a direct-to-
consumer fashion. The interpretation of this question may have altered how respondents 
answered the question. In addition, clinical utility, in the context of the survey, was not well 
defined and was therefore open to interpretation. The exact meaning of clinical utility that was 
intended was that prenatal exome sequencing has diagnostic value (comparable to existing 
prenatal diagnostic tools, as discussed in the background section of this document) and could be 
beneficial to patients in the clinical setting to provide answers for fetal anomalies/recurrent 
miscarriages. Any respondent may have had their own definition of clinical utility in mind, 
which would alter how they answered the question and how they discussed clinical utility as a 
factor influencing their opinions. 
This survey was limited to current prenatal and laboratory genetic counselors because 
they will be the first genetic counselors dealing with this testing in the prenatal setting. Due to 
the flexible nature of the genetic counseling field, many counselors who are not currently in 
either of these roles may likely transition to one or both in the future. Future research may 
consider these questions in a wider scope, addressing genetic counselors in all specialties. 
Genetic counselors who did not meet criteria for this survey may still be involved with policy 
decisions about the implementation of this testing and it is therefore important to gauge their 
opinions as well. Future research should also consider the knowledge base and opinions of other 
prenatal providers such as medical geneticists and OBGYNs, as they will undoubtedly play a 
role in the future of exome sequencing in the prenatal setting. 
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4.3 PUBLIC HEALTH SIGNIFICANCE 
Genetic counselors often serve as gatekeepers to important genetic testing. The American 
College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic 
Counselors (NSGC) explicitly mention the importance of involving genetic counselors in the 
testing process in many of their policy statements, with some statements even recommending 
that testing not be provided without genetic counselor involvement.9,11,10 While prenatal exome 
sequencing is currently offered on a limited basis only by a few genetic testing laboratories 
outside of a research setting, it is highly likely that this testing will be widely available in the 
near future.28,29 It is therefore important to gauge the opinions of genetic counselors toward this 
testing as they will be the ones at the front-lines when it is implemented. WES and TES have 
already been shown to have utility in the prenatal setting,27,28 and could therefore be useful in 
providing patients with information about recurrent abnormal pregnancies as well as risks for 
miscarriage, while giving more accurate predictions of recurrence risk. This research has 
identified several barriers that would be important to address prior to implementation of WES or 
TES in the prenatal setting, as well as identifying overall opinions regarding appropriate clinical 
situations for testing, which may help to guide policy decisions and recommendations about such 
testing. Addressing the issues identified by this research can help to more seamlessly introduce 
WES and/or TES to the prenatal setting, providing the most benefit to patients. 
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4.4 CONCLUSIONS 
Genetic counselors’ views and opinions toward prenatal exome sequencing were gauged by 
providing specific scenarios in which this testing might be offered, types of incidental findings 
that might be reported, counseling scenarios that could arise as a result of this testing, and factors 
associated with this testing that affected these opinions. Demographic information was collected 
in order to determine if any significant differences in opinions existed based on this information. 
More than half of respondents would at least support prenatal exome sequencing (WES or TES) 
after other diagnostic testing had returned as negative or inconclusive. The majority of 
respondents would support prenatal exome sequencing as long as it was either limited to 
clinically indicated cases or phenotypically-driven TES. Perceived patient ability to understand 
the scope of the testing and the perceived clinical utility of exome in the prenatal setting where 
the two largest factors influencing opinions on prenatal exome sequencing. More than 70% of 
respondents would be more likely to support prenatal WES or TES if educational resources were 
provided. 
The results of this research help to identify areas of need to be addressed prior to 
implementation of this testing. This may help to facilitate a discussion between laboratories 
wishing to offer this testing and clinical genetic counselors who will be providing this testing to 
patients, as well as help guide management guidelines about when the testing should be offered. 
There are a significant number of factors that need to be considered as this testing becomes more 
widely available commercially, including important ethical concerns that should also be 
addressed. 
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APPENDIX A – COVER LETTER AND SURVEY 
A.1 COVER LETTER 
Survey - Student research project - Genetic counselors’ views and opinions on the possible 
implementation of prenatal exome sequencing 
I am a second year graduate student in the genetic counseling program at the University 
of Pittsburgh and I am conducting research to assess the views and opinions of prenatal and 
laboratory genetic counselors about the possible implementation of exome sequencing in a 
prenatal setting. This research project has been approved by the University of Pittsburgh IRB. 
You are invited to participate in this study by taking part in an online survey. Counselors 
who are currently practicing in the prenatal clinical setting (part-time or full-time) as well as 
counselors currently working in either academic or commercial testing laboratories (part-time or 
full-time) are eligible to participate in this survey. 
Because of the speed at which new genetic testing technology has previously been 
implemented for use in prenatal diagnosis/screening, exome sequencing could soon be available 
to clinicians who provide prenatal care. Your answers to this survey will help to better 
understand the needs and opinions of prenatal and laboratory counselors before the possible 
availability of prenatal exome sequencing through testing laboratories. 
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Please forward this survey to any genetic counselors who are not NSGC members, who 
fit the above eligibility criteria, and who would be interested in participating in this study. 
This survey takes approximately 15-20 minutes to complete.  Please follow the link 
below to access the survey: You may contact me with any questions regarding this survey: 
tnz1@pitt.edu 
Thank you in advance for your participation in this study, Tricia Zion, Genetic 
Counseling Student, University of Pittsburgh Graduate School of Public Health. 
 
A.2 SURVEY 
Introduction and Consent 
Thank you for participating in this survey. The survey will take approximately 20-30 minutes to 
complete. Your participation is completely voluntary and can be discontinued at any time. You 
may skip any questions you are uncomfortable with answering. By completing this survey, you 
are consenting to participate in this research study. 
 
Terms that will be used in this survey: 
Exome Sequencing 
Exome sequencing analyzes only the protein-coding region of the genome. It is currently 
typically used for cases in which all other genetic testing options have been exhausted and no 
clinically significant findings have been detected. It may also be used for patients with multiple 
findings not consistent with any one specific syndrome. Currently, exome sequencing finds a 
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clinically significant genetic change in approximately 30% of cases. Similar to chromosomal 
microarray analysis, the large scope of this testing means there is a greater likelihood of 
detecting variants of unknown clinical significance. In addition, incidental genetic findings 
unrelated to patient phenotype may also be discovered.  
 
Incidental Findings 
Because exome sequencing looks at all of the protein coding genes, it is possible that 
genetic findings unrelated to the patient’s clinical phenotype will be detected. The American 
College of Medical Genetics has issued a recommended list of 25 genes in which clinically 
actionable variants should be reported for all patients undergoing exome sequencing. 
(https://www.acmg.net/docs/IF_Statement_Final_7.24.13.pdf) 
 Patients are able to opt in or out of receiving incidental findings and may be able to 
choose specific categories of genes in which they do or do not want to receive results. 
 
Targeted Exome Sequencing 
Targeted exome sequencing allows the laboratory to focus on genes known to be 
associated with a patient’s clinical phenotype. This essentially results in a custom-made panel 
that can reduce interpretation time, reduce the likelihood for variants of unknown clinical 
significance, and eliminates the option for incidental genetic findings. Targeted exome 
sequencing is currently being offered through several genetic testing laboratories and helps to 
reduce the length and difficulty of the consent/disclosure process for the clinical counselor. 
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Q1. Do you currently work in a laboratory (commercial or academic) position or a clinical 
prenatal position? 
[ ] Laboratory position [ ]Clinical Prenatal Position [ ] I work in both laboratory and prenatal 
positions [ ] I do not work in either a laboratory or a clinical prenatal position 
 
Q2. Have you ever ordered whole exome sequencing for a patient? 
[ ] Yes  [ ] No 
Q3. Have you ever analyzed whole exome sequencing in a laboratory setting? 
[ ] Yes [ ] No 
Q4. If you work/have worked in a prenatal clinic – On average how much time do you spend 
preparing for each case you see? 
[ ] 10-20 minutes [ ] 20-40 minutes [ ] 40-60 minutes [ ] Longer than 1 hour [ ] I have never 
worked in a prenatal clinic 
Q5. If you work/have worked in a prenatal clinic – On average, how long do your sessions 
typically last? 
[ ] 20 minutes [ ] 30 minutes [ ] 40 minutes [ ] 50 minutes [ ] 60 minutes or more 
Q6. Please indicate how much you agree or disagree with the following statements regarding 
prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly 
agree) 
Prenatal exome sequencing should be offered: 
-When there are structural abnormalities on ultrasound and previous diagnostic testing (e.g. 
microarray) has come back negative or inconclusive 
-When there are structural abnormalities on ultrasound before other diagnostic testing is offered 
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-In the context of providing a genetic diagnosis for neonatal management rather than pregnancy 
management (e.g. a diagnosis prenatally would help guide medical management decisions in the 
neonatal period) 
-Whenever a patient expresses interest in having prenatal exome 
Q7. Please indicate how much you agree or disagree with the following statements regarding 
prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly 
agree) 
I would be comfortable: 
-Providing pre-test counseling for exome sequencing in a prenatal setting 
-Disclosing and explaining variants of unknown clinical significance 
-Helping a patient make pregnancy management decisions based on the results of prenatal exome 
sequencing 
-Locating resources (e.g. support groups, specialty clinics) for patients based on the results of 
prenatal exome sequencing 
Q8. Please indicate how much you agree or disagree with the following statements regarding 
incidental findings for prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 
4=agree, 5=strongly agree) 
I believe: 
-Incidental findings from the ACMG recommended list should be reported 
-Incidental findings for hereditary cancer genes should be reported 
-Incidental findings that reveal carrier status should be reported 
-Incidental findings for adult-onset conditions should be reported 
-Incidental findings for childhood-onset conditions should be reported 
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-Patients should be able to choose from any of the above categories without restriction 
Q9. Please indicate how much you agree or disagree with the following statements regarding 
incidental findings for prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 
4=agree, 5=strongly agree) 
I would be comfortable: 
-Counseling patients about incidental findings in a pre-test counseling session 
-Disclosing and explaining incidental findings results in a prenatal setting 
-Helping a patient to make pregnancy management decisions based on the results of incidental 
findings from prenatal exome sequencing 
-Locating resources (e.g. support groups, specialty clinics) for patients based on incidental 
findings from prenatal exome sequencing 
Q10. Have you ever ordered targeted exome sequencing for a patient? 
[ ] Yes [ ] No 
Q11. Have you ever analyzed a targeted exome in a laboratory setting? 
[ ] Yes [ ] No 
Q12. Which of the following would you support in a prenatal setting? 
[ ] Whole exome sequencing [ ] Targeted exome sequencing [ ] Whole exome sequencing AND 
targeted exome sequencing [ ] Neither 
Q13. Please indicate how much you agree or disagree with the following statements regarding 
targeted prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 
5=strongly agree) 
Targeted prenatal exome sequencing should be offered; 
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-When there are structural abnormalities on ultrasound and previous diagnostic testing (e.g. 
microarray) has come back negative or inconclusive 
-When there are structural abnormalities on ultrasound before other diagnostic testing is offered 
-In the context of providing a genetic diagnosis for neonatal management rather than pregnancy 
management (e.g. a diagnosis prenatally would help guide medical management decisions in the 
neonatal period) 
-Whenever a patient expresses interest in having targeted prenatal exome 
Q14. Please indicate how much you agree or disagree with the following statements regarding 
targeted prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 
5=strongly agree) 
I would be comfortable:  
-Providing pre-test counseling for exome sequencing in a prenatal setting 
-Disclosing and explaining variants of unknown clinical significance 
-Helping a patient make pregnancy management decisions based on the results of prenatal exome 
sequencing 
-Locating resources (e.g. support groups, specialty clinics) for patients based on the results of 
prenatal exome sequencing 
Q15. Would you support genetic testing laboratories offering prenatal exome sequencing? 
[ ] Yes, only if access was restricted to cases with a clear clinical benefit 
[ ] Yes, only if it were a phenotype-driven targeted exome 
[ ] Yes, in any situation 
[ ] No, I would not support laboratories offering this testing in any situation 
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Q16. Please indicate how much you agree or disagree with the following statements about exome 
sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly agree) 
-I understand the clinical utility of exome sequencing 
-I feel exome sequencing could be clinically useful in a prenatal setting 
Q17. Please indicate how much you agree or disagree with the following statements about 
prenatal exome sequencing. (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, 5=strongly 
agree) 
-I would like commercial laboratories to make this testing available to clients 
-I am more comfortable with the idea of prenatal microarray than prenatal exome sequencing 
(whole exome sequencing or targeted exome sequencing) 
-I would be more likely to support the use of prenatal exome if a medical geneticist was there to 
help me disclose results 
-I would be more likely to support prenatal exome sequencing if educational/training 
opportunities were offered to help prepare for its implementation 
Final Questions – the following two questions are the last exome related questions in the survey. 
This will include an option for you to express specific or detailed answers, after which you will 
be linked to demographic questions and the survey will end. 
Q18. Which of the following aspects of prenatal exome sequencing contributed to your answers 
to this survey (Check all that apply) 
-Perceived difficulty (or lack of difficulty) in properly counseling patients on the purpose of 
prenatal exome sequencing 
-The number of genetic counselors available to handle the added workload of exome sequencing 
in a prenatal setting 
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-The amount of funding for positions to handle the added workload of exome sequencing in a 
prenatal setting 
-The amount of time allotted for a prenatal session 
-Perceived ability of patients to handle the amount of information provided from this testing 
-Turnaround time of exome sequencing tests 
-Perceived difficulty (or lack of difficulty) in dealing with billing/insurance issues 
-Current technology (noninvasive prenatal testing, chromosomal microarray analysis) is 
sufficient and appropriate for identifying genetic causes of abnormal ultrasound results 
-Current technology (noninvasive prenatal testing, chromosomal microarray analysis) IS NOT 
sufficient for identifying genetic causes of abnormal ultrasound results 
-Clinical utility for exome sequencing in a prenatal setting 
-Personal understanding of the clinical utility of exome sequencing 
-Personal beliefs (please explain) 
-Other (see below) 
Q19. Are there any additional reasons you think exome sequencing should or should not be 
offered in a prenatal setting? (This question is optional, but responses are highly encouraged to 
fully encompass the scope of factors affecting opinions on prenatal exome) 
D1. Gender 
[ ] Male [ ] Female 
D2. Age 
[ ] 20-24 [ ] 25-34 [ ] 35-44 [ ] 45-54 [ ] 55-64 [ ] 65 or older [ ] Prefer not to say 
D3. How long have you been working as a genetic counselor? 
[ ] Less than 1 year [ ] 1-5 years [ ] 5-10 years [ ] 10 years or longer 
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D4. What specialties of genetic counseling have you worked in? (Check all that apply) 
[ ] Prenatal (specify how many years) [ ] Pediatric (specify how many years) [ ] Cancer (specify 
how many years) [ ] Adult (specify how many years) [ ] Cardiology (specify how many years) [ ] 
Metabolic (specify how many years) [ ] Academic Laboratory (specify how many years) [ ] 
Commercial Laboratory (specify how many years) [ ] Other – please specify (specify how many 
years) 
D5. What specialty of genetic counseling do you currently work in? (Check all that apply) 
[ ] Prenatal [ ] Pediatric [ ] Cancer [ ] Adult [ ] Cardiology [ ] Metabolic [ ] Academic Laboratory 
[ ]Commercial Laboratory [ ]Other – please specify 
D6. How long have you been working in your current position? 
D7. In what state/province do you currently practice? (skip this question if you would prefer not 
to answer/your region is not on the list) 
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The above-referenced project has been reviewed by the Institutional Review 
Board.  Based on the information provided, this project meets all the necessary criteria 
for an exemption, and is hereby designated as "exempt" under section 
45 CFR 46.101(b)(2) 
 
 
Please note the following information: 
• Investigators should consult with the IRB whenever questions arise about 
whether planned changes to an exempt study might alter the exempt status. Use 
the "Send Comments to IRB Staff" link displayed on study workspace to 
request a review to ensure it continues to meet the exempt category.  
 
• It is important to close your study when finished by using the "Study 
Completed" link displayed on the study workspace. 
 
• Exempt studies will be archived after 3 years unless you choose to extend the 
study. If your study is archived, you can continue conducting research activities 
as the IRB has made the determination that your project met one of the required 
exempt categories.  The only caveat is that no changes can be made to the 
application. If a change is needed, you will need to submit a NEW Exempt 
application. 
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
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